Literature DB >> 6831630

Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety.

A Bargiotti, A M Casazza, G Cassinelli, A Di Marco, S Penco, G Pratesi, R Supino, A Zaccara, F Zunino, F Arcamone.   

Abstract

New 4'-C-methyl analogues of daunorubicin, synthesized by the coupling reaction of daunomycinone with 1-chloroderivatives of protected 4-C-methyldaunosamine analogues, were chemically transformed to the corresponding doxorubicin analogues. Their cytotoxic effect against HeLa cells, ability to bind to DNA, and in vivo toxicity and antitumor activity were compared with those of daunorubicin, doxorubicin, and their 4'-O-methyl analogues. The cytotoxic effect of the new anthracyclines could be correlated with their ability to bind to DNA and with their toxicity in experimental animals; however, the antitumor effectiveness did not seem to be related to these parameters. In general all the compounds retained a remarkable antitumor activity at their optimal doses. The most active compound against P388 leukemia was 4'-O-methyldoxorubicin, which was also more active than doxorubicin against L1210 leukemia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831630     DOI: 10.1007/bf00446215

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  HETEROGENEITY OF THE INTERACTION OF DNA WITH ACRIFLAVINE.

Authors:  R K TUBBS; W E DITMARS; Q VANWINKLE
Journal:  J Mol Biol       Date:  1964-08       Impact factor: 5.469

2.  Cellular pharmocodynamics of several anthrocycline antibiotics.

Authors:  N R Bachur; M Steele; W D Meriwether; R C Hildebrand
Journal:  J Med Chem       Date:  1976-05       Impact factor: 7.446

3.  Relationship between activity and amino sugar stereochemistry of daunorubicin and adriamycin derivatives.

Authors:  A Di Marco; A M Casazza; R Gambetta; R Supino; F Zunino
Journal:  Cancer Res       Date:  1976-06       Impact factor: 12.701

4.  Interaction of new derivatives of daunorubicin and adriamycin with DNA.

Authors:  E Arlandini; A Vigevani; F Arcamone
Journal:  Farmaco Sci       Date:  1977-05

5.  Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.

Authors:  W D Meriwether; N R Bachur
Journal:  Cancer Res       Date:  1972-06       Impact factor: 12.701

6.  The interaction of aminocridines with nucleic acids.

Authors:  A Blake; A R Peacocke
Journal:  Biopolymers       Date:  1968       Impact factor: 2.505

7.  Quantitative models for growth inhibition of human leukemia cells by antitumor anthracycline derivatives.

Authors:  P M Kanter; H S Schwartz
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

8.  Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety.

Authors:  A Di Marco; A M Casazza; T Dasdia; A Necco; G Pratesi; P Rivolta; A Velcich; A Zaccara; F Zunino
Journal:  Chem Biol Interact       Date:  1977-12       Impact factor: 5.192

9.  Experimental evaluation of anthracycline analogs.

Authors:  A M Casazza
Journal:  Cancer Treat Rep       Date:  1979-05

10.  Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues.

Authors:  G Cassinelli; D Ruggieri; F Arcamone
Journal:  J Med Chem       Date:  1979-02       Impact factor: 7.446

View more
  3 in total

1.  Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.

Authors:  B T Hill; L Y Dennis; X T Li; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study.

Authors:  S Eridani; N G Slater; A K Singh; T C Pearson
Journal:  Blut       Date:  1985-06

3.  Formation of DNA-adducts and induction of DNA-crosslinks and chromosomal aberrations by the new potent anthracycline antitumor antibiotics: morpholinodaunomycin, cyanomorpholinodaunomycin and cyanomorpholinoadriamycin.

Authors:  J Westendorf; G Groth; G Steinheider; H Marquardt
Journal:  Cell Biol Toxicol       Date:  1985-01       Impact factor: 6.691

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.